Navigation Links
Eisai Inc. Announces Non-Exclusive Licensing Agreement with Generic Drug Manufacturer to Provide Generic Version of donepezil HCl 23 mg
Date:8/29/2013

WOODCLIFF LAKE, N.J., Aug. 29, 2013 /PRNewswire/ -- Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of generic pharmaceuticals that grants certain rights, including the right to market and offer for sale a generic version of donepezil hydrochloride 23 mg and a non-exclusive license to Eisai Intellectual Property covering donepezil hydrochloride 23 mg, including U.S. Patent No. 8,481,565. This agreement applies to the United States only.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs. Media InquiriesInvestor InquiriesMarcia Diljak

Alex ScottEisai Inc.

Eisai Inc.(201) 746-2236

(201) 746-2177


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Launches New Website Providing Employers with Educational Resource for Obesity Management
2. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
3. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
4. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
5. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
6. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
7. FDA Grants Orphan Drug Status To Eisais Lenvatinib
8. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
9. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
10. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
11. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... August 27, 2020 , ... The GHT Companies , a ... initiative for Feeding San Diego with a press conference at its manufacturing ... the final check of $5,000.00+ representing an overall donation result exceeding $30,000 to Feeding ...
(Date:8/26/2020)... ... , ... AseptiScope, a privately funded San Diego, California based, clinical innovation company, ... , “AseptiScope is pleased to receive this recognition,” said Kelly Powers, AseptiScope ... their hands, goggles on their eyes, covers on their shoes, and gowns on their ...
(Date:8/26/2020)... ... August 26, 2020 , ... Unscrupulous ... systems kill Coronavirus. While air purification technologies, including GreenTech Environmental’s proprietary methods, have ... Ebola, no air purification system has published results of singular and scientific testing ...
Breaking Medicine Technology:
(Date:9/3/2020)... , ... September 03, 2020 , ... ... Approval for Sunrise Technologies WALI wireless parking lot controller. This advanced LED wireless ... glare, reducing light trespass, and protecting the night sky against light pollution. Leo ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... a new practice in Glendale. While the office will be the first ... breast augmentation, tummy tucks, buttock augmentation (Brazilian butt lift), as well as rhinoplasty, ...
(Date:9/1/2020)... ... , ... Feeding Matters , the first organization in the world dedicated ... pleased to announce that the U.S. Centers for Disease Control and Prevention (CDC) has ... edition of the U.S. International Classification of Diseases (ICD ) on October 1, ...
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... ... Surgeon with specialty fellowship training in aesthetic surgery of the face, breast, and ... – the only female-owned premier boutique plastic surgery and aesthetic practice in Southwest ...
(Date:8/31/2020)... ... August 31, 2020 , ... The Lymphoma ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... Anniversary of Blood Cancer Awareness Month (BCAM) and its international Light it ...
Breaking Medicine News(10 mins):